A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant
Latest Information Update: 11 Jun 2023
At a glance
- Drugs Ad26 Mos HIV (Primary) ; Ad26 Mos4 HIV (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms TRAVERSE
- Sponsors Janssen Vaccines and Prevention
- 05 Jul 2022 Status changed from active, no longer recruiting to completed.
- 15 Mar 2022 Planned End Date changed from 5 Apr 2023 to 4 May 2022.
- 15 Feb 2022 Planned End Date changed from 1 Apr 2023 to 5 Apr 2023.